Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 9/20 | 0.52 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | ACACA | Q13085 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1083719 | 0.92 | CCR5 (0.51) | CCR5LMNA | |
| SCHEMBL1083710 | 0.88 | CCR5 (0.48) | CCR5LMNA | |
| SCHEMBL1083738 | 0.85 | ACACB (0.50) | CCR5ACACBACACAALDH1A1LMNA | |
| SCHEMBL1083698 | 0.85 | CCR5 (0.44) | CCR5ACACBACACAKCNH2TACR1 | |
| SCHEMBL1083736 | 0.84 | L3MBTL3 (0.44) | CCR5ALDH1A1LMNATACR1KDM4E | |
| SCHEMBL1083740 | 0.81 | ACACB (0.47) | CCR5ACACBACACAALDH1A1LMNA | |
| SCHEMBL1083693 | 0.81 | ACACB (0.50) | CCR5ACACBACACAKCNH2 | |
| SCHEMBL1083726 | 0.81 | ACACB (0.42) | CCR5ACACBACACAKCNH2ALDH1A1 | |
| SCHEMBL1083742 | 0.81 | CYP2C9 (0.48) | CCR5ACACBACACAKCNH2SLC6A7 | |
| SCHEMBL1083716 | 0.80 | L3MBTL3 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153805-B2 | Biaryl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-10 | — | — | US | claimed |
| US-20090048238-A1 | NOVEL BIARYL DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-02-19 | — | — | US | claimed |
| US-8153805-B2 | Biaryl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153805-B2 | Biaryl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153805-B2 | Biaryl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-10 | — | — | US | disclosed |
| WO-2009043747-A2 | N-HETEROCYCLIC BIARYL CARBOXAMIDES AS CCR RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-09 | — | — | WO | disclosed |
| US-20090048238-A1 | NOVEL BIARYL DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090048238-A1 | NOVEL BIARYL DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090048238-A1 | NOVEL BIARYL DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048238-A1 | NOVEL BIARYL DERIVATIVES | CCR3, CCRL2, CCR2 | CCR5 5/4885ACACB 2262/4885ACACA 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.